A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE ISSN： 1753-4658 出版频率： Continuous publication 出版社： SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP   出版社网址： http://www.uk.sagepub.com/journalsProdDesc.nav?prodId=Journal201860&ct_p=title&crossRegion=asia 期刊网址： http://tar.sagepub.com/ 影响因子： 4.031 主题范畴： RESPIRATORY SYSTEM 变更情况： Newly Added by 2014 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal eISSN: 1753-4666 ISSN: 1753-4658 Therapeutic Advances in Respiratory Disease Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.   The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in respiratory disease, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of respiratory disease, including emerging therapies for chronic obstructive pulmonary disease, asthma, pulmonary hypertension and the exacerbations caused by infections and smoking. It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online. For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact: Commercial Sales Team, London, UK Tel. +44 20 7336 1205 Email. reprints@sagepub.co.uk This journal is a member of the Committee on Publication Ethics (COPE) Aims & Scope NOW INDEXED IN MEDLINE! Therapeutic Advances in Respiratory Disease is an internationally peer reviewed journal whose primary aim is the dissemination and development of knowledge about the pharmacological treatment of respiratory diseases. The journal's scope includes emerging therapies for chronic obstructive pulmonary disorder, asthma, pulmonary hypertension and the exacerbations caused by infections and smoking. 1. The purpose of the Journal is to publish (in the English language) articles, reviews and scholarly comment which have been judged worthy of publication by appropriate specialists and accepted by the Editor on studies relating to respiratory disease, pharmacology and medicine. The Journal is for all professionals concerned with respiratory disease and is a forum for all views on related subjects. The editorial board welcomes articles of current interest on original research, reviews and clinical studies. 2. The Journal will be international in the sense that it will seek, wherever possible, to publish material from authors with an international reputation and articles that are of interest to an international audience. 3. In pursuit of the above the journal shall: (i) draw on and include high quality work from the international community of scholars including those in the major countries of Europe, Australasia, the United States, other parts of the Americas, countries in the Third World and elsewhere with due representation for considerations of the readership. The Journal shall include work representing the major areas of interest in contemporary research in respiratory disease and medicine. (ii) avoid bias in favour of the interests of particular schools or directions of research or particular political or narrow disciplinary objectives to the exclusion of others; (iii) ensure that articles are written in a terminology and style which makes them intelligible, not merely within the context of a particular discipline or abstract mode, but across the domain of relevant disciplines. The Journal's scope includes emerging therapies for chronic obstructive pulmonary disorder (COPD), asthma, pulmonary hypertension, the acute exacerbations caused by infections, and smoking and its cessation. Peer review statement Therapeutic Advances in Respiratory Disease strongly endorses the value and importance of peer review in scholarly journals publishing. All original research and review articles submitted to the Journal will be subject to comment and external review by no less than two reviewers adhering to a single blind peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer(s) requests a preference for their identity to be revealed. Manuscripts are reviewed as rapidly as possible, and a first editorial decision is generally reached within 2-3 weeks of submission. Authors are requested to suggest the names, affiliations and contact information of up to six individuals who may be suitable to serve as referees, but the Editors are under no obligation to use all or any of these individuals as reviewers. Manuscripts are reviewed initially by the Editors and only those papers that meet the scientific and editorial standards of the Journal, and fit within the aims and scope of the Journal, will be sent for outside review. Abstracting/Indexing Chemical Abstracts Service (CAS)  Cultures, Langues, Textes: La Revue de Sommaires (Prev. Science Culture)  Medline  Medscape Instructions to Authors Manuscript Submission Correspondence and online submission Publication categories Writing your manuscript  Reference style 4.1 Corresponding author contact details Research ethics Publication statement Peer review statement Journal contributor’s publishing agreement Declaration of conflicting interests policy Authorship Funding Acknowledgement Informed consent Permissions After acceptance 10.1 Proofs 10.2 E-Prints and complimentary copies 10.3 SAGE production 10.4 OnlineFirst publication 10.5 SAGE Choice Editorial Board Managing Editor: Philip Shaw SAGE Publications Ltd, London, UK Associate Editors: Antonio Anzueto University of Texas, San Antonio, TX, USA Donald Sin St Paul’s Hospital, Vancouver, BC, Canada Tobias Welte Medizinische Hochschule, Hannover, Germany Tom Wilkinson Southampton General Hospital, Southampton, UK   Editorial Board: Ian M Adcock National Heart and Lung Institute, London, UK Gary Anderson Michigan State University, USA Isabella Annesi-Maesano INSERM and UPMC Paris VI, Paris, France Peter Barnes Imperial College London, UK Eric Bateman UCT Lung Institute, Cape Town, South Africa Francesco Blasi University of Milan, Italy Vito Brusasco University of Genoa, Italy Peter Calverley University of Liverpool, UK Ulrich Costabel Ruhrland Klinik, Essen, Germany Maria Montes de Oca Hospital Universitario de Caracas, Caracas, Venezuela Walter De Wever University Hospitals Leuven, Belgium Roy Goldie Flinders University, Adelaide, Australia Christhina-Georgia Gratziou University of Athens School of Medicine, Greece Rudolf M. Huber University of Munich, Germany Marc Humbert Université Paris-Sud, France Masakazu Ichinose Wakayama Medical University, Wakayama, Japan Jan Lötvall Goteborg University, Sweden Helgo Magnussen Hospital Grosshansdorf, Schleswig Holstein Universität, Germany David Mannino University of Kentucky, Lexington, USA Fernando Martinez A Alfred Taubman Health Care Center, Ann Arbor, USA Maria-Gabriella Matera Dipartimento di Medicina Sperimentale, The Second University of Naples, Naples, Italy Paolo Montuschi Catholic University of the Sacred Heart, Rome, Italy Robert Naeije Free University of Brussells, Belgium Clive Page GKT School of Biomedical Science, London, UK Reynold Panettieri University of Pennsylvania Medical Center, Philadelphia, USA Irfan Rahman University of Rochester Medical Center, USA Stephen Rennard Nebraska Medical Centre, Omaha, USA Cesare Saltini University of Rome, "Tor Vergata", Italy Sundeep Salvi Chest Research Foundation Joan B. Soriano Fundacio Caubet-Cimera Illes Balears, Bunyola, Spain Monica Spiteri University Hospital of North Staffs, Stoke on Trent, UK Robert Stockley University of Birmingham , UK Neil C. Thomson University of Glasgow, Scotland Manuel Tuñón de Lara Université Victor Sé, Bordeaux, France J. Christian Virchow University Medical Clinics, Rostock, Germany Claus Vogelmeier University Hospital Gießen und Marburg, Marburg, Germany Grant Waterer University of Western Australia, Crawley, WA, Australia Richard Zuwallack St Francis Hospital and Medical Center, Hartford, USA